The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

Medically reviewed by Suzanne Fisher, RD Hypoglycemia (low blood sugar) treatments will depend on the severity of symptoms ...

Eighteen hospitalized male diabetic patients, thirty to sixty-nine years of age, were studied. The known duration of the diabetes in the group ranged from one to twenty-five years. All patients ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and role in therapy of vildagliptin for the treatment of type 2 diabetes mellitus were reviewed.